In this on-demand webinar, our experts explore how Lonza’s Early Development Services support the successful progression of bioconjugates—such as antibody–drug conjugates (ADCs)—from late discovery through early preclinical development.
Discover how our integrated, end-to-end capabilities help address critical early-stage challenges, including molecule selection, developability assessment, safety evaluation, and manufacturability, enabling a smoother transition toward IND.
Watch on demand to learn how our advanced technologies and integrated developability strategies help you:
- De-risk your bioconjugate program early
- Minimize patient safety risks
- Improve decision-making in early development
- Build a strong foundation for scalable manufacturing and downstream development
Why Watch This Webinar?
Address complexity early
Gain practical insights into overcoming developability, safety, and manufacturability challenges across ADCs and novel bioconjugates—before they impact timelines, costs, or clinical success.
Accelerate smarter decisions
Learn how integrated assessments and enabling technologies support faster, data-driven decisions, helping you streamline your path to IND and reduce downstream risk.
Build for long-term success
Understand the value of partnering with a CDMO offering end-to-end bioconjugate development, from late discovery to clinical and commercial manufacturing—ensuring continuity, scalability, and efficiency.
